1257998-65-4

Basic information

• Product Name: Octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride
• Synonyms: Octahydropyrazino[2,1-C][1,4]Oxazine Hydrochloride;Octahydropyrazino[2,1-C][1,4]Oxazine Hydrochloride(WX110611S1);OCTAHYDROPYRAZINO[2,1-C][1,4]OXAZINE 2HCL
• CAS NO: 1257998-65-4
• Molecular Formula: C7H16Cl2N2O
• Molecular Weight: 215.12074
• Mol File: 1257998-65-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride(1257998-65-4)
• EPA Substance Registry System: Octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride(1257998-65-4)

Safety Data

• Hazardous Substances Data: 1257998-65-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride is used as a research compound for its potential anxiolytic and sedative properties. It is valued for its ability to modulate the GABAA receptor, which is crucial for the treatment of anxiety and other central nervous system disorders.
Used in the Treatment of Anxiety:
In the field of mental health, Octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride is used as a potential therapeutic agent for anxiety disorders. Its mechanism of action involves enhancing the inhibitory neurotransmission mediated by GABA, which can help in reducing anxiety symptoms.
Used in the Development of Central Nervous System Therapies:
Octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride is utilized in the development of treatments for various central nervous system disorders. Its role as a positive allosteric modulator of the GABAA receptor positions it as a candidate for the management of conditions that involve dysregulation of the GABAergic system.

Upstream product

• 1089280-09-0 (3R)-5-oxo-N,4-bis(phenylmethyl)-3-morpholinecarboxamide 
• 1152110-17-2 1-phenyl-N-{[(3S)-4-(phenylmethyl)-3-morpholinyl]methyl}methanamine 
• 1089280-12-5 ethyl oxo((phenylmethyl){[(3S)-4-(phenylmethyl)-3-morpholinyl]methyl}amino)acetate 
• 1089280-11-4 (9aS)-8-(phenylmethyl)hexahydropyrazino[2,1-c][1,4]oxazine-6,7-dione 
• 106973-37-9 (3S)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 
• 1126432-05-0 (9aR)-8-(phenylmethyl)octahydropyrazino[2,1-c][1,4]oxazine 
• 385802-30-2 (3S)-5-oxo-N,4-bis(phenylmethyl)-3-morpholinecarboxamide 
• 106973-36-8 (3R)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 
• 1089280-13-6 (9aS)-8-(phenylmethyl)octahydropyrazino[2,1-c][1,4]oxazine 

Downstream Products

• 1152110-20-7 [(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl}hydrazino)-3-oxopropyl][(phenylmethyl)oxy]formamide 
• 1152107-25-9 GSK1322322 
• 1089759-42-1 (S)-octahydropyrazino[2,1-c][1,4]oxazine 

Relevant articles and documents

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3- oxopropyl}hydroxyformamide compounds of Formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity and in treatment methods for bacterial infections

THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents

THIAZOLE AND OXAZOLE KINASE INHIBITORS

The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.